Allergan told its stockholders not to respond to Pershing Square Capital Management's proposal to replace a majority of the board.» Read More
Cramer honestly believes that regular investors can outperform the broad market every day, including today, simply by following this strategy.
The "Fast Money" traders share their final trades of the day.
*Teva, Ranbaxy to pay $150,000 each to settle with New York State. Feb 18- The New York Attorney General and the U.S. units of Ranbaxy Laboratories Ltd and Teva Pharmaceutical Industries Ltd have settled claims that an agreement between the two drugmakers unlawfully restricted competition.
Feb 18- The New York Attorney General and the U.S. units of Ranbaxy Laboratories Ltd and Teva Pharmaceutical Industries Ltd have settled claims that an agreement between the two drugmakers unlawfully restricted competition. Teva and Ranbaxy will pay the New York state $300,000 and have agreed to refrain from similar agreements in the future.
Some of Tuesday's midday movers:
Actavis agreed to acquire rival drug maker Forest Laboratories in a deal worth as much as $25 billion.
Some of Thursday's midday movers:
Markets are in wait-and-see mode ahead of Friday's jobs report, but there are a few events Thursday that could sway the market's direction.
Talking Squawk, the "Squawk Box" blog, provides tidbits, insights and sarcastic reflections on the WEEK THAT WAS and the WEEK TO COME.
Some of Wednesday's midday movers:
Sanofi's Lemtrada multiple sclerosis treatment has failed to win approval from U.S. regulators, dealing a setback to a drug which was at the heart of the French drugmaker's $20 billion takeover of biotech firm Genzyme.
Take a look at some of Friday's midday movers: Twitter, Textron, Sprint
Some of the names on the move ahead of the open.
Jim Cramer often advocates viewing a sell-off as opportunity. Often, but not always.
Take a look at some of Wednesday's midday movers:
Take a look at some of Monday's midday movers:
GlaxoSmithKline's pharmaceutical and vaccine sales to China tumbled 61 percent in the third quarter, with the drugmaker hit by an ongoing bribery investigation.
The economy may have added as many as 200,000 jobs in July amid the backdrop of a pickup in manufacturing activity and fewer layoffs.
Check out which companies are making headlines after the bell Thursday:
Traders are looking past ISM manufacturing data and weekly jobless claims, to the July nonfarm payrolls because it will be key in the Fed's decision making process.